Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol Myers Squibb Company $BMY Holdings Raised by Caprock Group LLC
04:44am, Friday, 24'th Apr 2026
Caprock Group LLC boosted its stake in Bristol Myers Squibb Company (NYSE: BMY) by 20.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The ins
Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade)
02:25am, Friday, 24'th Apr 2026
Bristol-Myers Squibb remains a solid, undervalued investment but is no longer a compelling 'Buy' due to muted growth prospects. BMY's growth portfolio now surpasses its legacy portfolio, yet overall r
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
11:02am, Thursday, 23'rd Apr 2026
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
08:00am, Thursday, 23'rd Apr 2026
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announce
61,789 Shares in Bristol Myers Squibb Company $BMY Bought by CPC Advisors LLC
04:44am, Wednesday, 22'nd Apr 2026
CPC Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commissi
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
12:30pm, Tuesday, 21'st Apr 2026
BMY stands out vs GILD, supported by a cheaper valuation, strong growth portfolio, and improving earnings outlook despite generic headwinds.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
10:41am, Tuesday, 21'st Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOn
Brighton Jones LLC Acquires 76,067 Shares of Bristol Myers Squibb Company $BMY
05:04am, Tuesday, 21'st Apr 2026
Brighton Jones LLC boosted its stake in Bristol Myers Squibb Company (NYSE: BMY) by 220.7% during the undefined quarter, according to the company in its most recent disclosure with the Securities and
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?
03:46pm, Monday, 20'th Apr 2026
BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook.
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 20'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BMY Stock: Analysts See 16% Upside and a Strong Buy
10:50am, Monday, 20'th Apr 2026
Bristol-Myers Squibb (NYSE:BMY | BMY Price Prediction) trades at $60.17 as of writing.
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
08:00am, Monday, 20'th Apr 2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific
Assetmark Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY
04:37am, Saturday, 18'th Apr 2026
Assetmark Inc. reduced its stake in Bristol Myers Squibb Company (NYSE: BMY) by 29.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff
03:35pm, Friday, 17'th Apr 2026
Bristol-Myers Squibb is deeply undervalued at 8.9x forward earnings due to overblown patent cliff fears on Eliquis and Opdivo. The Growth Portfolio now generates 55% of revenue, grew 17% in FY2025, an
